Bonaci-Nikolic Branka, Nikolic Milos M, Andrejevic Sladjana, Zoric Svetlana, Bukilica Mirjana
Institute of Allergy and Clinical Immunology, Clinical Centre of Serbia, Belgrade, Serbia and Montenegro.
Arthritis Res Ther. 2005;7(5):R1072-81. doi: 10.1186/ar1789. Epub 2005 Jul 13.
Clinical and serological profiles of idiopathic and drug-induced autoimmune diseases can be very similar. We compared data from idiopathic and antithyroid drug (ATD)-induced antineutrophil cytoplasmic antibody (ANCA)-positive patients. From 1993 to 2003, 2474 patients were tested for ANCA in the Laboratory for Allergy and Clinical Immunology in Belgrade. Out of 2474 patients, 72 (2.9%) were anti-proteinase 3 (PR3)- or anti-myeloperoxidase (MPO)-positive and their clinical and serological data were analyzed. The first group consisted of ANCA-associated idiopathic systemic vasculitis (ISV) diagnosed in 56/72 patients: 29 Wegener's granulomatosis (WG), 23 microscopic polyangiitis (MPA) and four Churg-Strauss syndrome. The second group consisted of 16/72 patients who became ANCA-positive during ATD therapy (12 receiving propylthiouracil and four receiving methimazole). We determined ANCA and antinuclear (ANA) antibodies by indirect immunofluorescence; PR3-ANCA, MPO-ANCA, anticardiolipin (aCL) and antihistone antibodies (AHA) by ELISA; and cryoglobulins by precipitation. Complement components C3 and C4, alpha-1 antitrypsin (alpha1 AT) and C reactive protein (CR-P) were measured by nephelometry. Renal lesions were present in 3/16 (18.8%) ATD-treated patients and in 42/56 (75%) ISV patients (p <0.001). Skin lesions occurred in 10/16 (62.5%) ATD-treated patients and 14/56 (25%) ISV patients (p <0.01). ATD-treated patients more frequently had MPO-ANCA, ANA, AHA, aCL, cryoglobulins and low C4 (p <0.01). ISV patients more frequently had low alpha1 AT (p = 0.059) and high CR-P (p <0.001). Of 16 ATD-treated patients, four had drug-induced ANCA vasculitis (three MPA and one WG), while 12 had lupus-like disease (LLD). Of 56 ISV patients, 13 died and eight developed terminal renal failure (TRF). There was no lethality in the ATD-treated group, but 1/16 with methimazole-induced MPA developed pulmonary-renal syndrome with progression to TRF. ANCA-positive ISV had a more severe course in comparison with ATD-induced ANCA-positive diseases. Clinically and serologically ANCA-positive ATD-treated patients can be divided into two groups: the first consisting of patients with drug-induced WG or MPA which resemble ISV and the second consisting of patients with LLD. Different serological profiles could help in the differential diagnosis and adequate therapeutic approach to ANCA-positive ATD-treated patients with symptoms of systemic disease.
特发性和药物性自身免疫性疾病的临床和血清学特征可能非常相似。我们比较了特发性和抗甲状腺药物(ATD)诱导的抗中性粒细胞胞浆抗体(ANCA)阳性患者的数据。1993年至2003年,贝尔格莱德过敏与临床免疫学实验室对2474例患者进行了ANCA检测。在2474例患者中,72例(2.9%)抗蛋白酶3(PR3)或抗髓过氧化物酶(MPO)呈阳性,并对其临床和血清学数据进行了分析。第一组由56/72例诊断为ANCA相关特发性系统性血管炎(ISV)的患者组成:29例韦格纳肉芽肿(WG)、23例显微镜下多血管炎(MPA)和4例变应性肉芽肿性血管炎。第二组由16/72例在ATD治疗期间ANCA呈阳性的患者组成(12例接受丙硫氧嘧啶治疗,4例接受甲巯咪唑治疗)。我们通过间接免疫荧光法测定ANCA和抗核(ANA)抗体;通过酶联免疫吸附测定法测定PR3-ANCA、MPO-ANCA、抗心磷脂(aCL)和抗组蛋白抗体(AHA);通过沉淀法测定冷球蛋白。通过散射比浊法测定补体成分C3和C4、α-1抗胰蛋白酶(α1AT)和C反应蛋白(CR-P)。16例接受ATD治疗的患者中有3例(18.8%)出现肾脏病变,56例ISV患者中有42例(75%)出现肾脏病变(p<0.001)。16例接受ATD治疗的患者中有10例(62.5%)出现皮肤病变,56例ISV患者中有14例(25%)出现皮肤病变(p<0.01)。接受ATD治疗的患者更常出现MPO-ANCA、ANA、AHA、aCL、冷球蛋白和低C4(p<0.01)。ISV患者更常出现低α1AT(p=0.059)和高CR-P(p<0.001)。16例接受ATD治疗的患者中,4例患有药物性ANCA血管炎(3例MPA和1例WG),12例患有狼疮样疾病(LLD)。56例ISV患者中,13例死亡,8例发展为终末期肾衰竭(TRF)。接受ATD治疗的组中无死亡病例,但1例由甲巯咪唑诱导的MPA患者发展为肺-肾综合征并进展为TRF。与ATD诱导的ANCA阳性疾病相比,ANCA阳性ISV的病程更严重。临床上和血清学上,ANCA阳性的ATD治疗患者可分为两组:第一组由类似于ISV的药物性WG或MPA患者组成,第二组由LLD患者组成。不同的血清学特征有助于对有全身疾病症状的ANCA阳性ATD治疗患者进行鉴别诊断和采取适当的治疗方法。